Anti-Cd19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Frontiers in Oncology- Switzerland
doi 10.3389/fonc.2019.00767
Full Text
Abstract
Available in
Date
August 19, 2019
Authors
Publisher
Frontiers Media SA